---
title: "Antibody therapy developer Electra upsizes IPO seeking nearly $350M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299464124.md"
description: "Electra Therapeutics upsized its U.S. IPO to raise nearly $350M, pricing 23.3M shares at $15 each on Nasdaq under ticker ETRA. The biotech plans to use proceeds for its lead asset ipsoprubart and working capital. Jefferies, TD Cowen, Evercore ISI, and Cantor are joint book-running managers."
datetime: "2026-09-18T14:45:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299464124.md)
  - [en](https://longbridge.com/en/news/299464124.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299464124.md)
generator: "portal-rs"
---

# Antibody therapy developer Electra upsizes IPO seeking nearly $350M


### Related Stocks

- [ETRA.US](https://longbridge.com/en/quote/ETRA.US.md)

## Related News & Research

- [OrbiMed Advisors Discloses Investment at Electra Therapeutics with 11.0% Stake](https://longbridge.com/en/news/300167793.md)
- [OrbiMed Advisors acquires 1,333,333 Electra Therapeutics shares for USD 20 million](https://longbridge.com/en/news/299946121.md)
- [Tesla Delivery Surprise Puts BYD Stock And Li Auto Shares In Focus](https://longbridge.com/en/news/300832979.md)
- [If I Could Only Buy 1 Space Stock for the Next Decade, It Wouldn't Be SpaceX or Rocket Lab](https://longbridge.com/en/news/300850222.md)
- [Electra Therapeutics adopts amended, restated bylaws effective at IPO close](https://longbridge.com/en/news/299678681.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**